Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Tandem Diabetes Care, Inc. or Envista Holdings Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Tandem Diabetes Care, Inc. and Envista Holdings Corporation compare based on key financial metrics to determine which better meets your investment needs.

About Tandem Diabetes Care, Inc. and Envista Holdings Corporation

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Latest Health Care Equipment & Supplies and Tandem Diabetes Care, Inc., Envista Holdings Corporation Stock News

As of September 4, 2026, Tandem Diabetes Care, Inc. had a $1.4 billion market capitalization, compared to the Health Care Equipment & Supplies median of $423.0 million. Tandem Diabetes Care, Inc.’s stock is down 9.5% in 2026, down 7.1% in the previous five trading days and up 60.61% in the past year.

Currently, Tandem Diabetes Care, Inc. does not have a price-earnings ratio. Tandem Diabetes Care, Inc.’s trailing 12-month revenue is $1.0 billion with a -6.1% net profit margin. Year-over-year quarterly sales growth most recently was 5.8%. Analysts expect adjusted earnings to reach $-0.667 per share for the current fiscal year. Tandem Diabetes Care, Inc. does not currently pay a dividend.

As of September 4, 2026, Envista Holdings Corporation had a $4.4 billion market cap, putting it in the 65th percentile of all stocks. Envista Holdings Corporation’s stock is up 25.7% in 2026, up 0.6% in the previous five trading days and up 31.28% in the past year.

Currently, Envista Holdings Corporation’s price-earnings ratio is 47.5. Envista Holdings Corporation’s trailing 12-month revenue is $2.9 billion with a 3.3% net profit margin. Year-over-year quarterly sales growth most recently was 7.1%. Analysts expect adjusted earnings to reach $1.533 per share for the current fiscal year. Envista Holdings Corporation does not currently pay a dividend.

How We Compare Tandem Diabetes Care, Inc. and Envista Holdings Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Tandem Diabetes Care, Inc. and Envista Holdings Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Tandem Diabetes Care, Inc. and Envista Holdings Corporation Stock Value Grades

Company	Ticker	Value
Tandem Diabetes Care, Inc.	TNDM	D
Envista Holdings Corporation	NVST	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Tandem Diabetes Care, Inc. has a Value Score of 25, which is Expensive. Envista Holdings Corporation has a Value Score of 56, which is Average.

The Value Stock Winner: No Clear Winner

Neither Tandem Diabetes Care, Inc. or Envista Holdings Corporation has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Tandem Diabetes Care, Inc. or Envista Holdings Corporation is the better investment when it comes to value.

Tandem Diabetes Care, Inc. and Envista Holdings Corporation’s Momentum Grades

Company	Ticker	Momentum
Tandem Diabetes Care, Inc.	TNDM	B
Envista Holdings Corporation	NVST	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Tandem Diabetes Care, Inc. has a Momentum Score of 80, which is Strong. Envista Holdings Corporation has a Momentum Score of 72, which is Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Tandem Diabetes Care, Inc. and Envista Holdings Corporation have a grade of B. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Tandem Diabetes Care, Inc. and Envista Holdings Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Tandem Diabetes Care, Inc.	TNDM	B
Envista Holdings Corporation	NVST	A

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Tandem Diabetes Care, Inc. has a Earnings Estimate Score of 62, which is Positive. Envista Holdings Corporation has a Earnings Estimate Score of 81, which is Very Positive.

The Earnings Estimate Revisions Grade Winner: Envista Holdings Corporation

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Envista Holdings Corporation has a better Earnings Estimate Revisions Grade than Tandem Diabetes Care, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Envista Holdings Corporation could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Tandem Diabetes Care, Inc. and Envista Holdings Corporation Grades

In addition to Value, Estimate Revisions and Momentum, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Tandem Diabetes Care, Inc. and Envista Holdings Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Tandem Diabetes Care, Inc. or Envista Holdings Corporation Stock?

Overall, Tandem Diabetes Care, Inc. stock has a Value Score of 25, Momentum Score of 80 and Estimate Revisions Score of 62.

Envista Holdings Corporation stock has a Value Score of 56, Momentum Score of 72 and Estimate Revisions Score of 81.

Comparing Tandem Diabetes Care, Inc. and Envista Holdings Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.